DYSKINESIA (TARDIVE)

DYSKINESIA (TARDIVE):

• 2023
• A single-center, real-life study on the use of medical cannabis in patients with dystonia. https://www.frontiersin.org/articles/10.3389/fneur.2023.1218300/full 
• 2019
• What is Dyskinesia and Can Cannabis Assist? (news – 2019)
  https://www.marijuanabreak.com/dyskinesia-and-cannabis
• Medical Marijuana For Tardive Dyskinesia (TD). (news – 2019)
  https://www.marijuanadoctors.com/conditions/tardive-dyskinesia-td/
• Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia. (Australia, full, 2019) https://www.sciencedirect.com/science/article/pii/S0969996119303213?via%3Dihub 
• TSFM mutations cause a complex hyperkinetic movement disorder with strong relief by cannabinoids. (Germany, 1st page, 2019) https://www.prd-journal.com/article/S1353-8020(18)30427-9/fulltext 
• Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia. (Brazil, abstract, 2019) https://link.springer.com/article/10.1007%2Fs12640-019-00109-8 
• 2018
• Medical Marijuana and Dyskinesia (news – 2018)  https://www.marijuanadoctors.com/resources/ailment-resources/medical-marijuana-dyskinesia/
• Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? (Brazil, full, 2018) https://www.frontiersin.org/articles/10.3389/fphar.2018.00482/full 
• Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology. (China, abstract, 2018) https://www.sciencedirect.com/science/article/abs/pii/S0166432817316212 
• The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. (Spain/ France/ UK/ China, abstract, 2018) https://www.sciencedirect.com/science/article/abs/pii/S0969996118301979 
• Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. (Brazil/ France, abstract, 2018) https://www.sciencedirect.com/science/article/abs/pii/S0889159118305828 
• 2017
• Can Cannabis Prevent Dyskinesia in Long-Term Treatment of Parkinson’s Disease?
  (news – 2017) https://psychedelictimes.com/can-cannabis-prevent-dyskinesia-in-long-term-treatment-of-parkinsons-disease/
• Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats. (Japan, link to PDF, 2017) https://www.researchgate.net/publication/317296817_Zonisamide_ameliorates_levodopa-induced_dyskinesia_and_reduces_expression_of_striatal_genes_in_Parkinson_model_rats 
• Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia. (Spain/ Sweden, abstract, 2017) https://www.sciencedirect.com/science/article/abs/pii/S0889159117304038?via%3Dihub 
• 2016
• Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats. (Brazil, full, 2016) https://www.frontiersin.org/articles/10.3389/fphar.2016.00343/full 
• Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action. (Brazil, abstract, 2016) https://www.sciencedirect.com/science/article/abs/pii/S096999611630153X 
• 2015
• The therapeutic potential of cannabinoids for movement disorders. (USA, full, 2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357541/ 
• Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. (Spain, full, 2015) https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.13215 
• Molecular Targets of Cannabidiol in Neurological Disorders. (UK, full, 2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604182/ 
• Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. (Spain, full, 2015) https://link.springer.com/article/10.1007/s00429-014-0823-8 
• Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. (USA, full, 2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604174/ 
• Cannabinoids for the Treatment of Movement Disorders. (USA, link to PDF, 2015) https://www.researchgate.net/publication/280327565_Cannabinoids_for_the_Treatment_of_Movement_Disorders 
• 2012
• Marijuana and Asperger’s Syndrome. (anecdotal – 2012)
  http://www.imapatientnotacriminal.org/marijuana-and-aspergers-syndrome-2/
• 2010
• Tardive Dystonia and the Use of Cannabis (letter/forum repost–2010) http://www.420magazine.com/forums/dystonia/169902-tardive-dystonia-use-cannabis.html
• Undated
• Tardive Dyskinesia and Marijuana Information: Treat Tardive’s With Cannabis (news–undated) https://unitedpatientsgroup.com/information-tardive-and-marijuana-treat-tardives-with-cannabis